Enzon Pharmaceuticals, Inc.
Biotech Specialty Pharma
685 Route 202/206
Bridgewater, NJ 8807 USA
phone: (908) 541-8600
fax: 908-575-9457
Symbol ENZN
Exchange NASDAQ
Founded 0
Employees
www.enzon.com
Research Sector Biotech Specialty Pharma
Summary Description
Enzon is a biopharmaceutical company dedicated to therapeutics to treat life-threatening diseases.
Management
Jeffrey Buchalter, Chairman and Chief Executive Officer; Paul Davit, Executive Vice President, Human Resources; Ralph del Campo, Executive Vice President, Technical Operations; Dr. Ivan Horak, Executive Vice President, Research and Development and Chief Scientific Officer; Craig Tooman, Executive Vice President, Finance and Chief Financial Officer
Ownership
Financials Mkt Cap :484


* numbers in thousands

 
Keywords

Comment | Printable Version | Mar. 17, 2007
If you work for Enzon Pharmaceuticals, Inc. and want to update this profile, click here


Description
Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat life-threatening diseases. The company has developed or acquired a number of market products, including pegintron, marketed by Schering-Ploug, and abelcet, which is marketed in North America by Enzon. Enzon's science-focused strategy includes an extensive drug development program that leverages the company's PEG modification and single-chain antibody ("SCA") technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional products, projects, and technologies.
Strategy
Enzon has several drug candidates in various stages of development, independently and with partners. The Enzon business model is built on a dual-prong strategy:-Pursuing an aggressive internal drug development and commercialization program that leverages its macromolecular engineering capabilities; and Complementing internal scientific and clinical programs with strategic transactions to enhance existing product offerings and the technology portfolio Enzon has leveraged its proprietary technologies with PEG and SCA's to become a leader in the field of macromolecular engineering. Through partnering, Enzon now has access to one of the broadest suits of drug delivery technologies in the industry.


2008-08-27-247